CTOs on the Move

C2i Genomics

www.c2i-genomics.com

 
C2i Genomics is the first company to offer post-surgery monitoring of cancer recurrence and progression by analyzing subtle changes in the pattern of the tumor`s DNA. Our liquid biopsy Whole Genome assay and cancer burden score will equip oncologists with vital timely information months to years before current monitoring methods are able to.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Funding

C2i Genomics raised $12M on 06/09/2020
C2i Genomics raised $100M on 04/15/2021

Similar Companies

VEXIOM HOLDINGS CORPORATION

VEXIOM HOLDINGS CORPORATION is a Atlanta, GA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

FirstLight Health Systems

FirstLight Health Systems is a Mora, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Alberta Conservation Association

Alberta Conservation Association is a Edmonton, AB-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Vestaron

Recent winner of the Green Chemistry award, Vestaron is leading a peptide-based revolution in crop protection. We are committed to providing growers with novel, effective chemistries that address proven targets. Our peptides overcome existing resistance issues while offering a desired safety profile for workers, beneficials and the environment. Initially, Vestaron is focused on a class of peptides that kills insect pests efficiently, but is safe for humans, birds, fish, pollinators and the environment. As part of this, the company has developed a proprietary platform for peptide optimization and fermentation-based peptide production that will allow development of a wide variety of biologic crop protection solutions. Vestaron is proud to bring you the Power of Peptides through the SPEAR® brand family - providing new technology with a unique mode of action in a biological solution equal to, and often better, than the synthetic options; creating the opportunity to incorporate a new IRAC Group 32 into rotation recommendations for resistance management.

Adaptimmune

Adaptimmune is a clinical stage biopharmaceutical company focused on novel cancer immunotherapy products based on its T-cell receptor platform. Established in 2008, the Company aims to utilize the body`s own machinery – the T-cell – to target and destroy cancer cells by using engineered, increased affinity T-cell receptors (TCRs) as a means of strengthening natural patient T-cell responses. Adaptimmune`s lead program is an affinity enhanced TCR therapeutic targeting the NY-ESO cancer antigen. Its NY-ESO TCR therapeutic candidate has demonstrated signs of efficacy and tolerability in Phase 1/2 trials in solid tumors and in hematologic cancer types. In June 2014, Adaptimmune announced that it had entered into a strategic collaboration and licensing agreement with GlaxoSmithKline (GSK) for the development and commercialization of the NY-ESO TCR program in partnership with GSK. In addition, Adaptimmune has a number of proprietary programs and its next TCR therapeutic candidate, directed at MAGE A-10, is scheduled to enter the clinic in 2015. The Company has identified over 30 intracellular target peptides preferentially expressed in cancer cells and is currently progressing eight of these through unpartnered research programs. Adaptimmune has over 150 employees and is located in Oxfordshire, UK and Philadelphia, USA.